Candel Therapeutics Publishes Phase 3 Trial Results for Aglatimagene
Candel Therapeutics announced the publication of results from its pivotal Phase 3 trial of Aglatimagene in The Lancet Oncology. The trial, which enrolled 745 patients with intermediate- to high-risk localized prostate cancer, demonstrated a 30% improvement in disease-free survival compared to radiotherapy alone. Candel noted the findings support a planned Biologics License Application submission in Q4 2026. "The publication of this pivotal phase 3 trial in The Lancet Oncology provides important peer-reviewed validation of the significance of these findings for patients with localized prostate cancer," said Paul Peter Tak, president and CEO of Candel.
